If you made any changes in Pure these will be visible here soon.

Personal profile


Dr. Donia Moujalled completed her PhD in 2012 at The Walter and Eliza Hall Institute of Medical Research in the Cell Death and Cell Signaling division, led by Prof. David Vaux. During her PhD, Dr. Moujalled examined the role of receptor interacting protein kinases in cell death induced by tumour necrosis factor receptor 1. She continued to work as a post-doctoral researcher in Prof. Vaux's lab 2012- 2013, recieving funding from The Cancer Austalia Foundation, to characterise RIPK3 and MLKL in necroptosis signaling induced by TNF.

In 2014, she moved to the Austrlian Centre for Blood Diseases, Monash University based at The Alfred Hospital. She joined the Leukemia Research Group, led by A/Prof. Andrew Wei. Her research focus is on developing in vivo pre-clinical models to examine  BH3 mimetic compounds targeting pro-survival proteins BCL-2 and MCL1 in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. 

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

External positions

Honorary, Alfred Hospital

2014 → …

Research area keywords

  • Acute myeloid leukaemia
  • Acute lymphoblastic leukaemia
  • apoptosis
  • BH3 mimetics
  • BCL-2
  • MCL1


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or